Item 8.01 Other Events.
On January 26, 2021, Vir Biotechnology, Inc. (the "Company") issued a press
release announcing initial data from its ongoing Phase 1 clinical trial of
VIR-3434 for chronic hepatitis B virus ("HBV") infection, which demonstrates
significant and rapid reduction in HBV surface antigen. A copy of the press
release is attached hereto as Exhibit 99.1 and is incorporated herein by
reference.
On January 27, 2021, the Company, Eli Lilly and Company ("Lilly") and
GlaxoSmithKline plc ("GSK") issued a press release announcing that the first
patient was dosed in Lilly's expanded BLAZE-4 clinical trial. Lilly has expanded
its ongoing BLAZE-4 trial to evaluate the administration of bamlanivimab
(LY-CoV555) 700mg with VIR-7831 (also known as GSK4182136) 500mg, two
neutralizing antibodies that bind to different epitopes of the SARS-CoV-2 spike
protein, in low-risk patients with mild to moderate COVID-19. A copy of the
press release is attached hereto as Exhibit 99.2 is being furnished and shall
not be deemed "filed" for the purposes of Section 18 of the Securities Exchange
Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated by reference
into any filing made by the Company under the Securities Act of 1933, as
amended, or the Exchange Act, except as shall be expressly set forth by specific
reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. Description
99.1 Press Release of the Company, dated January 26, 2021.
99.2 Press Release of the Company, dated January 27, 2021.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses